Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. News
  7. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Genmab : Darzalex Meets Main Endpoint in Light-Chain Amyloidosis Study

05/28/2020 | 02:27pm EDT

By Colin Kellaher

 

Genmab A/S on Thursday said a phase 3 study of the cancer drug Darzalex met its primary endpoint in the most common type of amyloidosis, a rare disease that occurs when an abnormal protein called amyloid builds up in a body's tissues and organs.

The Copenhagen biotechnology company said subcutaneous Darzalex in combination with cyclophosphamide, bortezomib and dexamethasone for patients with newly diagnosed light-chain amyloidosis met the primary endpoint of percentage of patients with hematologic complete response.

Genmab said the study was conducted by Johnson & Johnson's Janssen Biotech Inc. unit, which has an exclusive license to develop, manufacture and commercialize Darzalex under an August 2012 agreement.

Genmab said Janssen will discuss with health authorities the potential for a regulatory submission for the indication, adding that there are currently no approved treatments for the progressive disease.

Darzalex is already approved in several indications in multiple myeloma, a cancer that forms in a type of white blood cells called plasma cells and causes cancer cells to accumulate in the bone marrow.

U.S.-listed shares of Genmab were recently up 4.6% to $31.06. Johnson & Johnson shares gained 2.1% to $147.90.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
GENMAB A/S -1.69% 2792 Delayed Quote.15.31%
JOHNSON & JOHNSON -0.33% 171.305 Delayed Quote.9.16%
All news about GENMAB A/S
07/23PRESS RELEASE : Pfizer And BioNTech to Supply U.S. -2-
DJ
07/22GENMAB A/S : Major shareholder announcement for Genmab A/S
AQ
07/22JOHNSON & JOHNSON : Genmab Announces Net Sales of DARZALEX (daratumumab) for the..
AQ
07/21Major Shareholder Announcement
GL
07/21GENMAB A/S : receives royalties on worldwide net sales from Janssen Biotech, Inc..
PU
07/21GENMAB A/S : Says Darzalex Sales in Q2 Hit $1.43 Billion
MT
07/21PRESS RELEASE : Pfizer and BioNTech Announce -3-
DJ
07/21Genmab Announces Net Sales of DARZALEX« (daratumumab) for the Second Quarter ..
GL
07/21Genmab Announces Net Sales Results of Darzalex« (Daratumumab) for the Second ..
CI
07/19PRESS RELEASE : BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platf..
DJ
More news
Financials
Sales 2021 7 670 M 1 215 M 1 215 M
Net income 2021 2 131 M 338 M 338 M
Net cash 2021 15 048 M 2 384 M 2 384 M
P/E ratio 2021 93,7x
Yield 2021 -
Capitalization 186 B 29 366 M 29 415 M
EV / Sales 2021 22,2x
EV / Sales 2022 16,5x
Nbr of Employees 871
Free-Float 95,1%
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | GMAB | DK0010272202 | MarketScreener
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 2 840,00 DKK
Average target price 2 481,91 DKK
Spread / Average Target -12,6%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S15.31%27 394
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308